Log in
NYSE:IQV

Iqvia Stock Forecast, Price & News

$151.30
+3.23 (+2.18 %)
(As of 09/28/2020 03:43 AM ET)
Add
Compare
Today's Range
$146.03
Now: $151.30▼
$152.52
50-Day Range
$148.07
MA: $159.61▼
$169.75
52-Week Range
$81.79
Now: $151.30▼
$170.51
Volume1.79 million shs
Average Volume1.44 million shs
Market Capitalization$28.94 billion
P/E Ratio222.50
Dividend YieldN/A
Beta1.33
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Read More
Iqvia logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.48 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
Current SymbolNYSE:IQV
Previous Symbol
CUSIPN/A
CIK1478242
Webwww.iqvia.com
Phone919-998-2000

Debt

Debt-to-Equity Ratio2.04
Current Ratio1.10
Quick Ratio1.09

Price-To-Earnings

Trailing P/E Ratio222.50
Forward P/E Ratio26.45
P/E Growth2.86

Sales & Book Value

Annual Sales$11.09 billion
Price / Sales2.61
Cash Flow$11.58 per share
Price / Cash Flow13.06
Book Value$32.28 per share
Price / Book4.69

Profitability

EPS (Most Recent Fiscal Year)$5.94
Net Income$191 million
Net Margins1.21%
Return on Equity17.90%
Return on Assets4.71%

Miscellaneous

Employees67,000
Outstanding Shares191,271,000
Market Cap$28.94 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$151.30
+3.23 (+2.18 %)
(As of 09/28/2020 03:43 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Iqvia (NYSE:IQV) Frequently Asked Questions

How has Iqvia's stock been impacted by COVID-19?

Iqvia's stock was trading at $125.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IQV shares have increased by 20.6% and is now trading at $151.30.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Iqvia?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 1 hold rating and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Iqvia.

When is Iqvia's next earnings date?

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Iqvia.

How were Iqvia's earnings last quarter?

Iqvia Holdings Inc (NYSE:IQV) posted its earnings results on Wednesday, July, 22nd. The medical research company reported $1.18 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.06 by $0.12. The medical research company had revenue of $2.52 billion for the quarter, compared to analysts' expectations of $2.41 billion. Iqvia had a return on equity of 17.90% and a net margin of 1.21%. During the same quarter in the previous year, the company posted $1.53 earnings per share.
View Iqvia's earnings history.

What guidance has Iqvia issued on next quarter's earnings?

Iqvia updated its FY20 earnings guidance on Wednesday, July, 22nd. The company provided earnings per share (EPS) guidance of $6.10-6.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.87. The company issued revenue guidance of $11.0-11.1 billion, compared to the consensus revenue estimate of $10.73 billion.

What price target have analysts set for IQV?

17 brokers have issued twelve-month target prices for Iqvia's shares. Their forecasts range from $110.00 to $200.00. On average, they expect Iqvia's share price to reach $165.00 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price.
View analysts' price targets for Iqvia.

Who are some of Iqvia's key competitors?

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA).
View all competitors.

What other stocks do shareholders of Iqvia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), NVIDIA (NVDA), Micron Technology (MU), Endologix (ELGX), Chipotle Mexican Grill (CMG), Alibaba Group (BABA), Paypal (PYPL), salesforce.com (CRM) and Accenture (ACN).

Who are Iqvia's key executives?

Iqvia's management team includes the following people:
  • Mr. Ari Bousbib, Chairman, Pres & CEO (Age 58)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
  • Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 55)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
  • Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)

What is Iqvia's stock symbol?

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Who are Iqvia's major shareholders?

Iqvia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.75%), BlackRock Inc. (7.22%), Jackson Square Partners LLC (2.05%), Canada Pension Plan Investment Board (1.24%), Nuveen Asset Management LLC (1.15%) and FMR LLC (1.09%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, John Connaughton, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer, Ronald E Bruehlman and W Richard Staub.
View institutional ownership trends for Iqvia.

Which institutional investors are selling Iqvia stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Man Group plc, Canada Pension Plan Investment Board, Goldman Sachs Group Inc., FMR LLC, Nuveen Asset Management LLC, Marshall Wace LLP, and Macquarie Group Ltd.. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Michael J Evanisko, and Michael R Mcdonnell.
View insider buying and selling activity for Iqvia.

Which institutional investors are buying Iqvia stock?

IQV stock was bought by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Vanguard Group Inc., State of Tennessee Treasury Department, Nordea Investment Management AB, Bessemer Group Inc., Alyeska Investment Group L.P., Veracity Capital LLC, and Ninety One North America Inc..
View insider buying and selling activity for Iqvia.

How do I buy shares of Iqvia?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iqvia's stock price today?

One share of IQV stock can currently be purchased for approximately $151.30.

How big of a company is Iqvia?

Iqvia has a market capitalization of $28.94 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe.

What is Iqvia's official website?

The official website for Iqvia is www.iqvia.com.

How can I contact Iqvia?

Iqvia's mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.